SCHEMBL22236345

SCHEMBL22236345

CC(C)(C)OC(=O)N(Cc1ccc(C(=O)NN)cc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 6/20 0.53
▸ HDAC3 O15379 3/20 0.53
▸ HDAC2 Q92769 3/20 0.53
▸ NCOR2 Q9Y618 3/20 0.53
▸ LTB4R2 Q9NPC1 2/20 0.47
▸ HDAC6 Q9UBN7 4/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HDAC8 Q9BY41 2/20 0.46
▸ NR1H4 Q96RI1 2/20 0.46
▸ PTGES O14684 1/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.42
▸ PTPRB P23467 1/20 0.42
▸ PTPN11 Q06124 1/20 0.42
▸ AKT1 P31749 2/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28628157 0.87 LTB4R2 (0.56) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL20236489 0.86 HDAC1 (0.48) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL22236346 0.83 HDAC1 (0.52) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL20236425 0.82 HDAC1 (0.56) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL4315970 0.82 PTGES (0.54) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL18464032 0.81 LTB4R2 (0.57) HDAC1HDAC3HDAC2NCOR2LTB4R2
SCHEMBL22218294 0.81 PTPRB (0.53) HDAC1HDAC3HDAC2NCOR2HDAC6
SCHEMBL4332066 0.81 HDAC1 (0.48) HDAC1HDAC3HDAC2NCOR2HDAC6
SCHEMBL2484830 0.80 HDAC1 (0.49) HDAC1HDAC3HDAC2NCOR2HDAC6
SCHEMBL28218883 0.80 HDAC1 (0.54) HDAC1HDAC3HDAC2NCOR2LTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10717716-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2020-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717716-B2 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same HDAC1, HDAC5, HDAC2 HDAC1 1/4885HDAC3 5/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback